Futura Medical PLC has provided an update on the US launch of its lead product, Eroxon, in its HY 2024 results announcement. The company has confirmed that Haleon expects Eroxon to be available in the US before the end of this year. The trading remains in line with current market expectations for FY2024, and the company plans to give updated guidance on trading at the time of its Interim results in September. The current market expectations do not include any contribution from the US launch in FY2024.
Futura Medical PLC is the developer of innovative sexual health products, with a core strength in research, development, and commercialization of topically delivered gel formulations in sexual health products. Eroxon, the company's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). It is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addressing significant unmet needs in the ED market. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
The company's financial performance remains in line with current market expectations for FY2024, and the US launch of Eroxon is expected to contribute to its future performance. Futura Medical PLC plans to provide updated guidance on trading at the time of its Interim results in September. The company's focus on developing and commercializing innovative sexual health products, particularly Eroxon, reflects its commitment to addressing significant unmet needs in the ED market and providing effective solutions for men globally.